BioArctic AB : Increase of volatility
Entry price | Target | Stop-loss | Potential |
---|
SEK 71.6 |
SEK 86 |
SEK 64.8 |
+20.11% |
---|
Market participant are once again showing interest in shares in BioArctic AB (publ). The technical chart pattern now appears positive for the short term with new upside potential.
Strengths● Thanks to a sound financial situation, the firm has significant leeway for investment.
● The group usually releases upbeat results with huge surprise rates.
● Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● The company has insufficient levels of profitability.
● The company's "enterprise value to sales" ratio is among the highest in the world.
● The underlying tendency is negative on the weekly chart below the resistance at 71 SEK
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.